In patients with diabetes and a prior major adverse limb event, GLP-1s were associated with better outcomes compared with DPP ...

Find out how GLP-1 RAs reduce limb, heart, and kidney risks in high-risk diabetes patients. Keep reading to learn more.

The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

GLP 1 receptor agonists were associated with higher incident chronic cough in adults with type 2 diabetes, with risk ...

The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.

Association driven by fewer major amputations ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

GLP-1 drugs show a potential link to reduced epilepsy risk in people with type 2 diabetes. People taking GLP-1 drugs were 16% less likely to develop epilepsy than those on DPP-4 inhibitors.

An FDA database analysis shows that reported adverse skin events after GLP-1 receptor agonist use are rare but can include rash and pruritus, highlighting a need for further research, according to a ...